Repligen Corporation Stock News

Repligen Corporation (RGEN) CEO Anthony Hunt on Q3 2021 Results - Earnings Call Transcript

Repligen (RGEN) delivered earnings and revenue surprises of 21.88% and 8.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) beats earnings and sales estimates in the third quarter of 2021.

On Repligen's (RGEN) third-quarter earnings call, investor focus is likely to be on the sales performance of its product franchisees - filtration, chromatography, protein and process analytics.

Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT

The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last twenty

Repligen Corporation (NASDAQ: RGEN) has agreed to acquire privately-held Avitide Inc for approximately $150 million in cash and stock. The deal consideration includes $75 million in cash plus $75 mill

WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”),

Ralf Kuriyel, Senior VP and RD at Repligen (NASDAQ:RGEN), made a large insider sell on August 30, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Co

CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

Repligen is one of those prime companies that let you sleep well at night with a long history of stable performance. The company has shown 30% revenue growth over the past decade, and will lift the tr

The life sciences company reported better-than-expected second-quarter results.

Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. The company also raises its guidance for 2021.

Repligen Corp, Inc. (RGEN) CEO Anthony Hunt on Q1 2021 Results - Earnings Call Transcript